{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:56Z","timestamp":1793146676470,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00877-4","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T06:23:12Z","timestamp":1740982992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Gastrointestinal toxicity of antibody\u2013drug conjugates: a pharmacovigilance study using the FAERS database"],"prefix":"10.1186","volume":"26","author":[{"given":"Yanshuo","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"877_CR1","doi-asserted-by":"crossref","unstructured":"Paolo T, et al. Antibody\u2013drug conjugates: smart chemotherapy delivery across tumor histologies. CA: cancer J Clinicians. 2021;72(2):165\u201382.","DOI":"10.3322\/caac.21705"},{"issue":"1","key":"877_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"F Zhiwen","year":"2022","unstructured":"Zhiwen F, Shijun L, Sifei H, et al. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Therapy. 2022;7(1):93\u201393.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"877_CR3","first-page":"1","volume":"13","author":"J Wang","year":"2021","unstructured":"Wang J, Yongkun S, Tienan Z, et al. Expert consensus on the clinical application of antibody\u2013drug conjugates for the treatment of malignant tumors (2020 edition). Chin J Med Front (Electronic Edition). 2021;13(1):1\u201315.","journal-title":"Chin J Med Front (Electronic Edition)"},{"key":"877_CR4","doi-asserted-by":"publisher","first-page":"104429","DOI":"10.1016\/j.yrtph.2019.104429","volume":"107","author":"H Saber","year":"2019","unstructured":"Saber H, Simpson N, Ricks KT, et al. An FDA oncology analysis of toxicities associated with PBD-containing antibody\u2013drug conjugates. Regul Toxicol Pharmacol. 2019;107:104429.","journal-title":"Regul Toxicol Pharmacol"},{"key":"877_CR5","doi-asserted-by":"crossref","unstructured":"Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60190\u2013209.","DOI":"10.1016\/j.ejca.2016.02.025"},{"issue":"5","key":"877_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40264-020-00908-5","volume":"43","author":"M Kathryn","year":"2020","unstructured":"Kathryn M, Christopher SJ, M C K, et al. An evaluation of postmarketing reports with an outcome of death in the US FDA adverse event reporting system. Drug Saf. 2020;43(5):457\u201365.","journal-title":"Drug Saf"},{"issue":"6","key":"877_CR7","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"B Ruwen","year":"2016","unstructured":"Ruwen B, Leocadie HV, Thomas H, et al. OpenVigil FDA - Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS One. 2016;11(6):e0157753.","journal-title":"PLoS ONE"},{"issue":"4","key":"877_CR8","first-page":"785","volume":"12","author":"W Yan","year":"2023","unstructured":"Yan W, Bin Z, Haiyan Y, et al. A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil. [J] Androl. 2023;12(4):785\u201392.","journal-title":"[J] Androl"},{"key":"877_CR9","doi-asserted-by":"crossref","unstructured":"Haiyan Y, Zheng W, Moliang C, et al. A real-world data analysis of Topotecan in the FDA adverse event reporting system (FAERS) database. [J] Exp Opinion Drug Metabol Toxicol. 2023;19(4):217\u201323.","DOI":"10.1080\/17425255.2023.2219390"},{"key":"877_CR10","doi-asserted-by":"crossref","unstructured":"Caruso IGDL, Molfetta DS, et al. The real-world safety profile of Tirzepatide: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. J Endocrinol Invest. 2024;(prepublish):1\u20138.","DOI":"10.1007\/s40618-024-02441-z"},{"key":"877_CR11","doi-asserted-by":"crossref","unstructured":"Fattahi SA, Jafari M, Farahavar G, et al. Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments. Crit Rev Oncol\/Hematol. 2024;201:104437.","DOI":"10.1016\/j.critrevonc.2024.104437"},{"issue":"08","key":"877_CR12","first-page":"1678","volume":"47","author":"L Tian Aijun","year":"2024","unstructured":"Tian Aijun L. Nonclinical safety evaluation of antibody\u2013drug conjugates: focus on toxicological pathology examination. Drug Evaluation Res. 2024;47(08):1678\u201386.","journal-title":"Drug Evaluation Res"},{"issue":"5","key":"877_CR13","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","volume":"10","author":"T Junji","year":"2020","unstructured":"Junji T, Hiroji I, Ian K, et al. Targeting HER2 with trastuzumab Deruxtecan: A Dose-Expansion, phase I study in multiple advanced solid tumors. Cancer Discov. 2020;10(5):688\u2013701.","journal-title":"Cancer Discov"},{"issue":"1","key":"877_CR14","first-page":"95","volume":"81","author":"C Richard","year":"2021","unstructured":"Richard C, Anja L, M H B, et al. The 2021 updated European association of urology guidelines on metastatic urothelial carcinoma. Eur Urol. 2021;81(1):95\u2013103.","journal-title":"Eur Urol"},{"issue":"10","key":"877_CR15","first-page":"1017","volume":"44","author":"China guideline for pharmaceutical care on","year":"2022","unstructured":"China guideline for pharmaceutical care on anti-tumor antibody-based drugs. Chin J Oncol. 2022;44(10):1017\u201346.","journal-title":"Chin J Oncol"},{"key":"877_CR16","doi-asserted-by":"crossref","unstructured":"Zhiwen F, Jinmei L, Shijun L, et al. Treatment-related adverse events associated with HER2-Targeted antibody\u2013drug conjugates in clinical trials: a systematic review and meta-analysis. EClinicalMed. 2023;5(5):101795\u2013101795.","DOI":"10.1016\/j.eclinm.2022.101795"},{"issue":"5","key":"877_CR17","first-page":"1","volume":"7","author":"S Yukio","year":"2023","unstructured":"Yukio S, Susu Z, Yukihide O, et al. Toxicity profiles of antibody\u2013drug conjugates for anticancer treatment: a systematic review and meta-analysis. JNCI cancer Spectr. 2023;7(5):1\u201311.","journal-title":"JNCI cancer Spectr"},{"issue":"3S","key":"877_CR18","first-page":"S391","volume":"22","author":"Y Chen","year":"2016","unstructured":"Chen Y, Perales M, Li S, et al. Phase I multicenter trial of Brentuximab Vedotin for steroid refractory acute Graft-Vs.-Host disease (GVHD). Biol Blood Marrow Transplant. 2016;22(3S):S391\u2013391.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"877_CR19","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.3390\/jcm11185378","volume":"11","author":"R Christian","year":"2022","unstructured":"Christian R, Ulrike B, Manuela R, et al. Combining BeEAM with Brentuximab Vedotin for High-Dose therapy in CD30 positive lymphomas before autologous Transplantation\u2014A phase I study. J Clin Med. 2022;11(18):5378\u20135378.","journal-title":"J Clin Med"},{"key":"877_CR20","doi-asserted-by":"crossref","unstructured":"Christoph R, Christoph S, Jan-Henrik M, et al. Gemtuzumab Ozogamicin plus midostaurin in combination with standard intensive induction therapy in newly diagnosed AML: results from a Phase-I study. Blood. 2021;138(S1):2324\u20132324.","DOI":"10.1182\/blood-2021-150069"},{"key":"877_CR21","unstructured":"Xiujuan G, Jianli Z, Linxiaoxiao D, et al. Assessing real-world safety concerns of sacituzumab Govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system. Front Oncol. 2023;131276976\u20131276976."},{"issue":"5","key":"877_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s12282-023-01473-2","volume":"30","author":"RECB Michael","year":"2023","unstructured":"Michael RECB, Saro K, et al. HER2-targeted antibody-drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia. [J] Breast Cancer (Tokyo Japan). 2023;30(5):796\u2013801.","journal-title":"Breast cancer (Tokyo Japan)"},{"issue":"2","key":"877_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4254\/wjh.v5.i2.86","volume":"5","author":"KB Roula","year":"2013","unstructured":"Roula KB, Patrick RE, Nizar C, et al. Myxedema Ascites with high CA-125: case and a review of literature. World J Hepatol. 2013;5(2):86\u20139.","journal-title":"World J Hepatol"},{"issue":"22","key":"877_CR24","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.3748\/wjg.v19.i22.3502","volume":"19","author":"BL Kumar","year":"2013","unstructured":"Kumar BL, Adrian S. Nodular regenerative hyperplasia related portal hypertension in a patient with hypogammaglobulinaemia. World J Gastroenterol. 2013;19(22):3502\u20134.","journal-title":"World J Gastroenterol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00877-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00877-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00877-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T06:23:18Z","timestamp":1740982998000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00877-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00877-4","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We affirm the originality of this study, and it has not been submitted to any preprint server.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Submission declaration"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}